Kidney Cancer Clinical Trial

Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors

Summary

The purpose of this study is to evaluate BMS-986315 alone and in combination with nivolumab or cetuximab in participants with advanced solid tumors.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Participants must have histologic confirmation of advanced (metastatic, recurrent, and/or unresectable) squamous cell carcinoma of the head and neck (SCCHN), nonsmall cell lung cancer (NSCLC), or renal cell cancer (RCC) with measurable disease per RECIST 1.1
Participants expected to have received standard of care therapies including an available PD-(L)1 inhibitor
Eastern cooperative oncology group performance status of 0 or 1
Women of childbearing potential must agree to follow methods of contraception

Exclusion Criteria:

Participants with active, known or suspected autoimmune disease
Participants with a condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications
Uncontrolled or significant cardiovascular disease
History of or with active interstitial lung disease or pulmonary fibrosis
Prior participation in anti-natural killer cell receptor (anti-NKG2A) clinical study
History of allergy or hypersensitivity to study drug components

Other protocol-defined inclusion/exclusion criteria apply

Study is for people with:

Kidney Cancer

Phase:

Phase 1

Estimated Enrollment:

308

Study ID:

NCT04349267

Recruitment Status:

Recruiting

Sponsor:

Bristol-Myers Squibb

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 14 Locations for this study

See Locations Near You

Banner MD Anderson Cancer Center
Gilbert Arizona, 85234, United States
Local Institution
Baltimore Maryland, 21287, United States
Wake Forest Baptist Health
Winston-Salem North Carolina, 27157, United States
Sanford Clinic Clinical Research
Sioux Falls South Dakota, 57104, United States More Info
Steven Powell, Site 0028
Contact
605-328-8000
The West Clinic, P.C.
Germantown Tennessee, 38138, United States More Info
Daniel Vaena, Site 0001
Contact
901-598-1454
Local Institution
Capital Federal Distrito Federal, C1428, Argentina
Local Institution - 0014
Edmonton Alberta, T6X 1, Canada More Info
Site 0014
Contact
Local Institution - 0011
Vancouver British Columbia, V5Z 4, Canada More Info
Site 0011
Contact
Local Institution
Vancouver British Columbia, V5Z 4, Canada
Local Institution
Ottawa Ontario, K1H 8, Canada
Local Institution - 0004
Toronto Ontario, M5G 2, Canada More Info
Site 0004
Contact
Local Institution - 0005
Montreal Quebec, H2X 3, Canada More Info
Site 0005
Contact
Local Institution - 0013
Ottawa , K1H 8, Canada More Info
Site 0013
Contact
Local Institution
Recoleta Metropolitana, , Chile
Local Institution
Mexico city Distrito Federal, 06100, Mexico More Info
Site 0023
Contact
Local Institution - 0018
Monterrey Nuevo LEON, 66460, Mexico
Local Institution - 0017
San Luis Potosí SAN LUIS Potosi, 78250, Mexico

How clear is this clinincal trial information?

Study is for people with:

Kidney Cancer

Phase:

Phase 1

Estimated Enrollment:

308

Study ID:

NCT04349267

Recruitment Status:

Recruiting

Sponsor:


Bristol-Myers Squibb

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.